LIGAND PHARMACEUTICALS INC

Form 4 June 11, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

burden hours per

response...

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005
Estimated average

0.5

OMB APPROVAL

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

Name and Address of Report Herman Melanie J	orting Person *	2. Issuer Name and Ticker or Trading Symbol LIGAND PHARMACEUTICALS	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
		INC [LGND]			
(Last) (First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	Director 10% Owner Other (give title Other (specify		
11119 NORTH TORRE ROAD, SUITE 200	Y PINES	06/10/2015	below) below) Interim CFO		
(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
LA JOLLA, CA 92037		Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

	(City)	(State)	Zip) Table	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						
S	Title of ecurity (nstr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired ion(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
	Common tock	06/10/2015		M	1,500	A	\$ 11.91	4,486	D	
	Common tock	06/10/2015		M	875	A	\$ 21.92	5,361	D	
	Common tock	06/10/2015		M	1,750	A	\$ 68.48	7,111	D	
	Common tock	06/10/2015		S	4,125	D	\$ 93.5 (1)	2,986	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 11.91	06/10/2015	06/10/2015	M	1,500	(2)	01/03/2022	Common Stock	1,500
Employee Stock Option (right to buy)	\$ 21.92	06/10/2015	06/10/2015	M	875	(3)	02/15/2023	Common Stock	875
Employee Stock Option (right to buy)	\$ 68.48	06/10/2015	06/10/2015	M	1,750	<u>(4)</u>	04/01/2024	Common Stock	1,750

Reporting Owners

Reporting Owner Name / Address	Keiationships					
•	Director	10% Owner	Officer	Other		
Herman Melanie J 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037			Interim CFO			

Reporting Owners 2

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Date

Signatures

/s/ Charles S. Berkman, For: Melanie J. Herman 06/11/2015

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$93.50 (1) to \$93.515, inclusive. The reporting person undertakes to provide, upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (2) Grant to reporting person of options, exercisable six months after the date of grant. The date of grant is 01/03/2012.
- (3) Grant to reporting person of options, exercisable six months after the date of grant. The date of grant is 02/15/2013.
- (4) Grant to reporting person of options, exercisable six months after the date of grant. The date of grant is 04/01/2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3